| 1 |
NCT01626014 |
Completed |
Interactive Educational Website for Women With Ovarian Cancer & Caregivers |
- Stage III Ovarian Cancer
- Stage IV Ovarian Cancer
- Recurrent Ovarian Cancer
- Fallopian Tube Cancer
|
- Behavioral: Usual Care Educational Website
- Behavioral: Prototype System
|
Interventional
|
Early Phase 1 |
- University of Minnesota - Clinical and Translational Science Institute
- University of Minnesota - Clinical and Translational Science Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Comparison of Number of Women Who Completed Advanced Directive
- Comparison of Number of Women Who Report Appointment with Palliative Care
|
53 |
Female |
18 Years and older (Adult, Older Adult) |
NCT01626014 |
2012NTLS005 |
|
August 2012 |
December 2014 |
December 2014 |
June 22, 2012 |
December 2, 2015 |
|
- Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota, United States
|
|
| 2 |
NCT00617188 |
Completed
Has Results |
Fulvestrant in Treating Patients With Recurrent Ovarian Epithelial Cancer |
|
|
Interventional
|
Phase 2 |
- Masonic Cancer Center, University of Minnesota
- Masonic Cancer Center, University of Minnesota
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Patients' Overall 90-Day Clinical Response as Measured by Response Evaluation Criteria in Solid Tumors (RECIST)
- Patients' Overall 90-Day Clinical Response as Measured by Modified Response Evaluation Criteria in Solid Tumors (Rustin)
- Median Number of Days to Treatment Termination
- (and 3 more...)
|
26 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00617188 |
CDR0000582821
UMN-2007LS003
UMN-WCC-49
UMN-0612M97626
IRUSFULV0062 |
|
June 2007 |
April 2008 |
July 2008 |
February 15, 2008 |
December 28, 2017 |
March 17, 2010 |
- Masonic Cancer Center at University of Minnesota
Minneapolis, Minnesota, United States
|
|
| 3 |
NCT00287859 |
Terminated |
Topotecan in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer |
- Fallopian Tube Cancer
- Ovarian Cancer
- Peritoneal Cavity Cancer
|
- Drug: topotecan hydrochloride
|
Interventional
|
Phase 1 |
- Masonic Cancer Center, University of Minnesota
- Masonic Cancer Center, University of Minnesota
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
5 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00287859 |
2004LS039
UMN-WCC-39 |
|
August 2004 |
December 2006 |
December 2006 |
February 7, 2006 |
November 29, 2017 |
|
- University of Minnesota Cancer Center
Minneapolis, Minnesota, United States
|
|
| 4 |
NCT00652899 |
Terminated
Has Results |
Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer |
- Fallopian Tube Cancer
- Ovarian Cancer
- Peritoneal Cavity Cancer
|
- Biological: Allopurinol
- Drug: Cyclophosphamide
- Drug: Fludarabine phosphate
- (and 3 more...)
|
Interventional
|
Phase 2 |
- Masonic Cancer Center, University of Minnesota
- Masonic Cancer Center, University of Minnesota
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Patients With In Vivo Expansion of Infused Allogeneic Natural Killer (NK) Cell Product
- Number of Patients Per Disease Response
- Median Number of Days to Progression
- Median Overall Survival Number of Days Patients Alive After Treatment
|
14 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00652899 |
2007LS138
UMN-MT2007-19R
UMN-WCC-53
UMN-0712M23462 |
|
March 2008 |
August 2009 |
August 2009 |
April 4, 2008 |
December 28, 2017 |
September 15, 2010 |
- Masonic Cancer Center at University of Minnesota
Minneapolis, Minnesota, United States
|
|
| 5 |
NCT02877862 |
Completed |
Mobile Phone Technology to Increase Genetic Counseling |
|
|
Interventional
|
Not Applicable |
- University of Minnesota - Clinical and Translational Science Institute
- University of Minnesota - Clinical and Translational Science Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- Uptake of cancer genetic counseling
|
104 |
Female |
18 Years and older (Adult, Older Adult) |
NCT02877862 |
MCC |
mAGIC |
February 2016 |
February 2018 |
February 2018 |
August 24, 2016 |
March 27, 2018 |
|
- University of Minnesota Medical Center
Minneapolis, Minnesota, United States
|
|
| 6 |
NCT00293293 |
Completed
Has Results |
Outcomes in Ovarian Cancer and Fallopian Tube Cancer Patients Using Complementary Alternative Medicine |
- Ovarian Cancer
- Peritoneal Primary Cancer
- Fallopian Tube Cancer
|
- Other: healing touch
- Other: massage therapy
- Other: hypnosis
- Drug: Standard chemotherapy
|
Interventional
|
Not Applicable |
- Masonic Cancer Center, University of Minnesota
- Randy Shaver Cancer Research Fund
- Masonic Cancer Center, University of Minnesota
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Quality of Life Comparison - Average FACT-O Scoring in Chemotherapy Alone vs. Chemotherapy Plus Complementary Alternative Medicine (CAM)
- Comparison of Mental Health Inventory (MHI) Questionnaire Results - Average for Chemotherapy Alone vs. Chemotherapy Plus CAM
- Number of Patients With Delays In Receiving Chemotherapy Alone
- (and 12 more...)
|
43 |
Female |
Child, Adult, Older Adult |
NCT00293293 |
2000NT790
UMN-WCC-30
0012M77821 |
|
May 2005 |
April 2009 |
January 2010 |
February 17, 2006 |
December 28, 2017 |
June 6, 2012 |
- Masonic Cancer Center at University of Minnesota
Minneapolis, Minnesota, United States
|
|
| 7 |
NCT00903630 |
Terminated
Has Results |
Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer |
- Fallopian Tube Cancer
- Ovarian Cancer
- Peritoneal Cavity Cancer
|
- Drug: Lenalidomide
- Drug: liposomal doxorubicin
|
Interventional
|
Phase 1
Phase 2 |
- Masonic Cancer Center, University of Minnesota
- Celgene Corporation
- Masonic Cancer Center, University of Minnesota
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Phase 1 - Maximum Tolerated Dose (MTD) of Lenalidomide When Combined With Fixed Dose Liposomal Doxorubicin in Women With Recurrent Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
- Phase 1 - Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)
- Phase 2 - Number of Subjects Achieving a Partial or Complete Response
- Phase 2 - Number of Subjects Who Are Progression-Free and Alive
|
15 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00903630 |
2008LS047
0805M32463
WCC #50
RV-OVAR-PI-0447 |
|
April 2009 |
August 2011 |
August 2011 |
May 18, 2009 |
December 28, 2017 |
January 18, 2017 |
- University of Minnesota Medical Center - Fairview
Minneapolis, Minnesota, United States
|
|
| 8 |
NCT01144442 |
Completed
Has Results |
WCC# 59 Hyperthermic Intraperitoneal Chemotherapy Utilizing Carboplatin in First Recurrence Ovarian Cancer |
- Ovarian Cancer
- Fallopian Tube Cancer
- Peritoneal Carcinoma
|
- Drug: Hyperthermic intraperitoneal chemotherapy with Carboplatin
- Other: Isotonic saline (perfusate)
- Procedure: Surgery
- (and 2 more...)
|
Interventional
|
Not Applicable |
- Masonic Cancer Center, University of Minnesota
- Masonic Cancer Center, University of Minnesota
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Clinical Response
- Feasibility of HIPC in Recurrent Disease Setting
- Quality of Life Measurements
- (and 2 more...)
|
10 |
Female |
16 Years to 90 Years (Child, Adult, Older Adult) |
NCT01144442 |
2009LS114
WCC# 59
1003M78874 |
|
August 2010 |
September 2012 |
September 2013 |
June 15, 2010 |
March 25, 2016 |
September 5, 2013 |
- Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota, United States
|
|
| 9 |
NCT02118285 |
Completed |
Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer |
- Ovarian Cancer
- Fallopian Tube Carcinoma
- Primary Peritoneal Carcinoma
|
- Drug: Fludarabine
- Drug: Cyclophosphamide
- Biological: NK cells
- (and 2 more...)
|
Interventional
|
Phase 1 |
- Masonic Cancer Center, University of Minnesota
- Incyte Corporation
- Masonic Cancer Center, University of Minnesota
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose of INCB024360
- Initial tumor response
- Duration of tumor response
- (and 2 more...)
|
2 |
Female |
18 Years and older (Adult, Older Adult) |
NCT02118285 |
2012LS101
MT2013-11 |
|
July 28, 2014 |
November 12, 2015 |
November 12, 2015 |
April 21, 2014 |
December 5, 2017 |
|
- University of Minnesota Masonic Cancer Center
Minneapolis, Minnesota, United States
|
|
| 10 |
NCT03054909 |
Recruiting |
IP ALT-803 Followed by SQ ALT-803 for Ovarian Cancer |
- FIGO Stage III and IV Ovarian Cancer
- FIGO Stage III and IV Fallopian Tube Cancer
- FIGO Stage III Primary Peritoneal Cancer
|
- Biological: ALT-803 Subcutaneous
- Biological: ALT-803 Intraperitoneal
|
Interventional
|
Phase 1 |
- Masonic Cancer Center, University of Minnesota
- Masonic Cancer Center, University of Minnesota
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression Free Survival
- Overall Survival
- ALT-803 associated toxicities
- Incidence of no recorded toxicity grade 3 or greater
|
28 |
Female |
18 Years and older (Adult, Older Adult) |
NCT03054909 |
2016LS034 |
|
September 19, 2017 |
December 31, 2020 |
December 31, 2021 |
February 16, 2017 |
September 26, 2018 |
|
- Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota, United States
|
|
| 11 |
NCT00610740 |
Completed
Has Results |
CerviPrep for Applying Topical Gemcitabine to the Cervix in Treating Patients With Primary Endometrial, Cervical, or Ovarian Epithelial Cancer |
- Cervical Cancer
- Endometrial Cancer
- Ovarian Cancer
|
- Drug: topical gemcitabine hydrochloride
- Procedure: therapeutic conventional surgery
|
Interventional
|
Phase 2 |
- Masonic Cancer Center, University of Minnesota
- Masonic Cancer Center, University of Minnesota
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Patients With Measurable Concentration of Gemcitabine in Uterine Vein (dFdC)
- Number of Patients With Measurable Concentration of Gemcitabine Metabolites in Uterine Vein (dFdU)
- Number of Patients With Measurable Peripheral Vein Concentration of dFdC
|
18 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00610740 |
2005LS071
WCC #44
UMN-0510M6486 |
|
July 2006 |
April 2008 |
April 2008 |
February 8, 2008 |
December 28, 2017 |
June 17, 2010 |
- University of Minnesota Cancer Center
Minneapolis, Minnesota, United States
|
|
| 12 |
NCT00331422 |
Terminated
Has Results |
Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer |
- Fallopian Tube Cancer
- Ovarian Cancer
- Peritoneal Cavity Cancer
|
- Drug: carboplatin
- Drug: paclitaxel
- Procedure: cytoreductive surgery
|
Interventional
|
Phase 2 |
- Masonic Cancer Center, University of Minnesota
- Masonic Cancer Center, University of Minnesota
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Patients Who Underwent Optimal Cytoreduction After Chemotherapy
- Patients' Overall Tumor Response as Measured by Response Evaluation Criteria in Solid Tumors (RECIST)
- Clinical Response Based on Serum Cancer Antigen 125 (CA-125) Concentration
- (and 3 more...)
|
7 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00331422 |
2004LS070
UMN-0409M64006
UMN- WCC-40 |
|
October 2005 |
March 2008 |
March 2009 |
May 31, 2006 |
December 28, 2017 |
February 8, 2010 |
- University of Minnesota Cancer Center
Minneapolis, Minnesota, United States
|
|
| 13 |
NCT00319748 |
Completed
Has Results |
Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers |
- Breast Cancer
- Ovarian Cancer
- Endometrial Cancer
- Cervical Cancer
|
|
Interventional
|
Phase 2 |
- Masonic Cancer Center, University of Minnesota
- Pfizer
- Masonic Cancer Center, University of Minnesota
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Patients With Tumor Response (Response Evaluation Criteria in Solid Tumors) Who Received All 24 Doses of 852A.
- Mean Difference Values for Interleukin 1 Receptor Antagonist (IKL1ra)
- Mean Difference Values for 10 kDa Interferon-gamma-induced Protein (IP-10)
- (and 4 more...)
|
15 |
All |
18 Years and older (Adult, Older Adult) |
NCT00319748 |
06US03IMP-852A
MT2006-02
2006LS005 |
|
April 2006 |
December 2007 |
December 2008 |
April 27, 2006 |
December 28, 2017 |
September 25, 2009 |
- Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota, United States
|
|
| 14 |
NCT00536523 |
Terminated |
Effect of Serotonin Level on Constipation Caused by Chemotherapy in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
- Constipation
- Bowel Obstruction
- Fallopian Tube Cancer
- (and 2 more...)
|
|
Observational
|
|
- University of Minnesota - Clinical and Translational Science Institute
- University of Minnesota - Clinical and Translational Science Institute
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Alterations in serotonin levels associated with increased constipation
|
13 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00536523 |
2007NT031
WCC-52 |
|
April 2007 |
December 2009 |
December 2009 |
September 28, 2007 |
August 22, 2014 |
|
- Masonic Cancer Center at University of Minnesota
Minneapolis, Minnesota, United States
|
|
| 15 |
NCT01970696 |
Recruiting |
International Ovarian & Testicular Stromal Tumor Registry |
- Ovarian Stromal Tumor
- Testicular Stromal Tumors
- Ovarian Small Cell Carcinoma
- DICER1 Syndrome
|
|
Observational
|
|
- Children's Hospitals and Clinics of Minnesota
- Children's Research Institute
- Dana-Farber Cancer Institute
- (and 11 more...)
|
Other / NIH |
- Observational Model: Other
- Time Perspective: Other
|
- DICER1 mutations in ovarian and testicular stromal tumors
- Clinical factors associated with outcome in ovarian and testicular stromal tumors
- Pathologic and Genetic Correlations
|
200 |
All |
up to 100 Years (Child, Adult, Older Adult) |
NCT01970696 |
International OTST Registry |
OTST |
December 2011 |
December 2020 |
|
October 28, 2013 |
November 6, 2017 |
|
- Children's Minnesota
Minneapolis, Minnesota, United States
|
|
| 16 |
NCT00218179 |
Completed |
Assessing the Link Between Smoke Carcinogen Biomarkers and Lung Cancer Risk - 1 |
- Tobacco Use Disorder
- Lung Cancer
|
|
Observational
|
|
- University of Minnesota - Clinical and Translational Science Institute
- National Institute on Drug Abuse (NIDA)
- University of Minnesota - Clinical and Translational Science Institute
|
Other / NIH |
- Observational Model: Case-Control
- Time Perspective: Retrospective
|
|
200 |
All |
55 Years to 74 Years (Adult, Older Adult) |
NCT00218179 |
NIDA-13333-1
P50DA013333 |
|
September 2005 |
December 2007 |
December 2007 |
September 22, 2005 |
January 23, 2017 |
|
- University of Minnesota
Minneapolis, Minnesota, United States
|
|
| 17 |
NCT01284075 |
Terminated |
The Effect of Guided Imagery and Music Therapy on Post-Operative Recovery After Gynecological Oncology Surgery |
- Ovarian Cancer
- Uterine Cancer
|
- Behavioral: Guided imagery and music therapy
- Behavioral: White Noise
- Other: No intervention
|
Interventional
|
Not Applicable |
- University of Minnesota - Clinical and Translational Science Institute
- University of Minnesota - Clinical and Translational Science Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Change in Mean Pain Score
- Use of Pain Medication
- Use of Anti-Nausea Medications
- (and 5 more...)
|
10 |
Female |
19 Years and older (Adult, Older Adult) |
NCT01284075 |
2009NTLS051
0912M75053 |
|
April 2010 |
April 2013 |
April 2013 |
January 26, 2011 |
August 22, 2014 |
|
- Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota, United States
|
|
| 18 |
NCT01105650 |
Completed
Has Results |
Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer |
- Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Cancer
- Breast Cancer
|
- Drug: Fludarabine
- Drug: Cyclophosphamide
- Drug: Cyclosporine
- (and 4 more...)
|
Interventional
|
Phase 2 |
- Masonic Cancer Center, University of Minnesota
- Masonic Cancer Center, University of Minnesota
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response Rate
- Time to Disease Progression
- Number of Participants With Progressive Disease at One Year
- Overall Survival
|
13 |
Female |
18 Years and older (Adult, Older Adult) |
NCT01105650 |
2009LS142
MT2009-30
1003M78876 |
|
July 2010 |
April 2014 |
April 2014 |
April 16, 2010 |
December 28, 2017 |
February 24, 2017 |
- Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota, United States
|
|
| 19 |
NCT03732950 |
Not yet recruiting |
Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer |
- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Primary Peritoneal Carcinoma
|
- Biological: Pembrolizumab
|
Interventional
|
Phase 2 |
- Jonsson Comprehensive Cancer Center
- National Cancer Institute (NCI)
- Jonsson Comprehensive Cancer Center
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall response rate (ORR) assessed per immune related Response Evaluation Criteria in Solid Tumors (irRECIST)
- Progression-free survival (PFS) assessed per irRECIST
- Incidence of adverse events graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
|
30 |
Female |
18 Years and older (Adult, Older Adult) |
NCT03732950 |
18-000643
NCI-2018-01550
P30CA016042 |
|
December 1, 2018 |
December 1, 2019 |
December 1, 2020 |
November 7, 2018 |
November 7, 2018 |
|
- UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, United States - University of Minnesota/Masonic Cancer Center
Minneapolis, Minnesota, United States - Mayo Clinic
Rochester, Minnesota, United States
|
|
| 20 |
NCT03213964 |
Recruiting |
Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int |
- Epithelial Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Cancer
|
- Biological: FATE-NK100
- Drug: Interleukin-2
|
Interventional
|
Phase 1 |
- Masonic Cancer Center, University of Minnesota
- Masonic Cancer Center, University of Minnesota
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Doze of FATE-NK100
- Objective Response Rate
- Progression-Free Survival (PFS)
- Overall Survival (OS)
|
16 |
Female |
18 Years to 75 Years (Adult, Older Adult) |
NCT03213964 |
2016LS186 |
|
October 19, 2017 |
November 1, 2019 |
April 1, 2020 |
July 11, 2017 |
September 26, 2018 |
|
- Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota, United States
|
|
| 21 |
NCT00432094 |
Recruiting |
Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors |
- Childhood Germ Cell Tumor
- Ovarian Cancer
- Teratoma
|
- Drug: carboplatin
- Drug: etoposide
- Drug: ifosfamide
- (and 5 more...)
|
Interventional
|
Phase 2 |
- Masonic Cancer Center, University of Minnesota
- Masonic Cancer Center, University of Minnesota
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival (OS)
- Disease-free survival (DFS)
- Engraftment of platelets
- (and 2 more...)
|
25 |
All |
10 Years to 69 Years (Child, Adult, Older Adult) |
NCT00432094 |
2006LS032
UMN-MT2005-21
UMN-0608M90586 |
|
December 19, 2006 |
January 2020 |
January 2020 |
February 7, 2007 |
February 12, 2019 |
|
- Masonic Cancer Center at University of Minnesota
Minneapolis, Minnesota, United States
|
|
| 22 |
NCT00879840 |
Active, not recruiting |
Assessment of Screening Modalities for Gynecologic Cancers |
- Ovarian Cancer
- Endometrial Cancer
- Controls Without Endometrial Cancer
- Controls Without Ovarian Cancer
|
|
Observational
|
|
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Case-Only
- Time Perspective: Retrospective
|
- Endometrial Cancer, ovarian cancer
|
118 |
Female |
50 Years to 120 Years (Adult, Older Adult) |
NCT00879840 |
999909121
09-C-N121 |
|
April 9, 2009 |
|
|
April 13, 2009 |
February 15, 2019 |
|
- Mayo Clinic, Rochester
Rochester, Minnesota, United States
|
|
| 23 |
NCT02432690 |
Active, not recruiting |
A Study of BBI503 in Asymptomatic Recurrent Ovarian Cancer Patients With CA-125 Elevation |
|
|
Interventional
|
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Disease Control Rate (DCR)
- Progression Free Survival (PFS)
- Progression Free Survival (PFS)-6
- (and 3 more...)
|
13 |
All |
18 Years and older (Adult, Older Adult) |
NCT02432690 |
BBI503-205GYN-M
BBI503-205GOV-M |
|
June 2015 |
December 2018 |
|
May 4, 2015 |
September 11, 2018 |
|
- Mayo Clinic
Rochester, Minnesota, United States
|
|
| 24 |
NCT01747798 |
Completed |
Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
- Recurrent Fallopian Tube Cancer
- Recurrent Ovarian Epithelial Cancer
- Recurrent Primary Peritoneal Cavity Cancer
|
- Drug: auranofin
- Other: laboratory biomarker analysis
|
Interventional
|
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Feasibility of conducting a 10-patient pilot study in asymptomatic ovarian cancer patients using CA 125 elevation
- Immunohistochemical staining for PKCt expression in resected tumor samples with Auranofin
- Patients' perceptions of learning of CA 125 elevation
- Oral gold therapy influence on the CA 125 levels
|
10 |
Female |
18 Years and older (Adult, Older Adult) |
NCT01747798 |
MC1162
NCI-2012-02207 |
|
November 2, 2012 |
January 10, 2014 |
April 6, 2015 |
December 12, 2012 |
October 8, 2018 |
|
- Mayo Clinic
Rochester, Minnesota, United States
|
|
| 25 |
NCT03456700 |
Suspended |
Auranofin and Sirolimus in Treating Participants With Ovarian Cancer |
- Ovarian Serous Tumor
- Recurrent Ovarian Carcinoma
|
- Drug: Auranofin
- Other: Laboratory Biomarker Analysis
- Drug: Sirolimus
|
Interventional
|
Phase 2 |
- Mayo Clinic
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Proportion of patients with a confirmed tumor response (partial response [PR] or complete response [CR] at least 4 weeks apart)
- Incidence of adverse event (AE)
- Overall survival (OS)
- (and 2 more...)
|
48 |
Female |
18 Years and older (Adult, Older Adult) |
NCT03456700 |
MC1761
NCI-2018-00321
P30CA015083 |
|
March 30, 2018 |
March 15, 2023 |
March 15, 2023 |
March 7, 2018 |
January 21, 2019 |
|
- Mayo Clinic
Rochester, Minnesota, United States
|
|
| 26 |
NCT02900560 |
Recruiting |
Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer |
- Epithelial Ovarian Cancer
|
- Drug: CC-486
- Biological: Pembrolizumab
|
Interventional
|
Phase 2 |
- Translational Research in Oncology
- Celgene
- Translational Research in Oncology
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of subjects with grade 3, 4, or 5 adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.03
- Number of subjects with with irPR, irCR or irSD as assessed by irRECIST
- Number of subjects with treatment emergent adverse events as assessed by CTCAE v4.03
|
20 |
Female |
18 Years and older (Adult, Older Adult) |
NCT02900560 |
TRIO026 |
|
December 20, 2016 |
December 2018 |
September 2019 |
September 14, 2016 |
October 15, 2018 |
|
- UCLA
Los Angeles, California, United States - Johns Hopkins University
Baltimore, Maryland, United States - University of Minnesota
Minneapolis, Minnesota, United States - Mayo Clinic
Rochester, Minnesota, United States
|
|
| 27 |
NCT01601548 |
Completed |
Cancer and Mindfulness-Based Cancer Recovery After Chemotherapy |
- Breast Cancer
- Colorectal Cancer
- Ovarian Cancer
- Uterine Cancer
|
- Behavioral: Mindfulness Based Cancer Recovery
|
Interventional
|
Not Applicable |
- Masonic Cancer Center, University of Minnesota
- Masonic Cancer Center, University of Minnesota
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Change in Medical Outcomes Study Scores - Intervention versus Control
- Change in Functional Assessment in Cancer Therapy Fatigue Scores - Intervention versus Control
- Change in Pittsburgh Sleep Quality Index Scores - Intervention versus Control
- (and 5 more...)
|
45 |
All |
18 Years and older (Adult, Older Adult) |
NCT01601548 |
2012NTLS014 |
|
July 2012 |
July 2013 |
July 2013 |
May 18, 2012 |
December 2, 2017 |
|
- Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota, United States
|
|
| 28 |
NCT00408590 |
Active, not recruiting
Has Results |
Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer |
- Ovarian Cancer
- Primary Peritoneal Cavity Cancer
|
- Biological: carcinoembryonic antigen-expressing measles virus
- Biological: oncolytic measles virus encoding thyroidal sodium iodide symporter
- Genetic: reverse transcriptase-polymerase chain reaction
- Other: laboratory biomarker analysis
|
Interventional
|
Phase 1 |
- Mayo Clinic
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Dose Limiting Toxicity
- Number of Responses (Complete and Partial, Stable and Progressive Disease)
- Change in CA-125 Levels From Baseline to Last Recorded Value (up to 18 Months)
- Time to Progression
|
37 |
Female |
18 Years to 120 Years (Adult, Older Adult) |
NCT00408590 |
CDR0000515008
P30CA015083
MC0117
1260-03
NCI-2009-01199 |
|
April 19, 2004 |
August 2012 |
December 2018 |
December 7, 2006 |
March 7, 2018 |
October 2, 2017 |
- Mayo Clinic
Rochester, Minnesota, United States
|
|
| 29 |
NCT01705288 |
Completed |
Implementation of a Rapid Recovery Program in Gynecologic Oncology Surgery: A Pilot Study |
- Cervical Cancer
- Uterine Endometrial Cancer
- Ovarian Cancer
|
- Procedure: Laparotomy
- Drug: intravenous narcotics
- Drug: standard anesthesia
- (and 2 more...)
|
Interventional
|
Early Phase 1 |
- Masonic Cancer Center, University of Minnesota
- Masonic Cancer Center, University of Minnesota
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Return to Function
- Comparison of Pain Assessment
- Comparison of Pain Medications Used
|
112 |
All |
19 Years and older (Adult, Older Adult) |
NCT01705288 |
2012LS096 |
|
January 1, 2013 |
August 24, 2016 |
August 24, 2016 |
October 12, 2012 |
February 10, 2017 |
|
- Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota, United States
|
|
| 30 |
NCT01511055 |
Terminated |
Intra-op Detection of Occult Ovarian Carcinoma Using a Folate-Alpha Receptor Specific Fluorescent Ligand |
|
|
Interventional
|
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Sensitivity and specificity of intra-operative imaging using Folate-FITC for identification of ovarian cancer metastatic to the peritoneum and lymph nodes
- Confirmation of low to absent rates of significant adverse events following a one-time dose of folate-FITC (EC-17).
|
21 |
Female |
18 Years and older (Adult, Older Adult) |
NCT01511055 |
11-002980 |
|
January 2012 |
June 2014 |
June 2014 |
January 18, 2012 |
June 8, 2015 |
|
- Mayo Clinic
Rochester, Minnesota, United States
|
|
| 31 |
NCT01139957 |
Unknown † |
Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer |
- Breast Carcinoma
- Fallopian Tube Carcinoma
- Ovarian Neoplasm
- Primary Peritoneal Carcinoma
|
- Procedure: Evaluation of Cancer Risk Factors
- Other: Quality-of-Life Assessment
- Other: Questionnaire Administration
- Procedure: Study of High Risk Factors
|
Observational
|
|
- Gynecologic Oncology Group
- National Cancer Institute (NCI)
- Gynecologic Oncology Group
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- Breast cancer mortality rates
- Ovarian cancer mortality rates
- Prospective incidence of ovarian cancer (including fallopian tube cancer), primary peritoneal cancer, breast cancer, and all cancer
- Quality of life
|
1916 |
Female |
30 Years and older (Adult, Older Adult) |
NCT01139957 |
GOG-8199
NCI-2011-02233
CDR0000674216
U10CA101165 |
|
June 2010 |
December 2015 |
|
June 9, 2010 |
June 8, 2015 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Gynecologic Oncology Group of Arizona
Phoenix, Arizona, United States - Mayo Clinic in Arizona
Scottsdale, Arizona, United States - (and 140 more...)
|
|
| 32 |
NCT03606486 |
Recruiting |
Lavage of the Uterine Cavity for Diagnosis of Ovarian Cancer |
- High Grade Ovarian Serous Adenocarcinoma
- Stage III Ovarian Cancer AJCC v8
- Stage IIIA Ovarian Cancer AJCC v8
- (and 7 more...)
|
- Other: Biospecimen Collection
- Other: Laboratory Biomarker Analysis
- Other: Lavage
- Other: Pap Smear
|
Interventional
|
Not Applicable |
- University of Washington
- National Cancer Institute (NCI)
- Minnesota Ovarian Cancer Alliance
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Sensitivity of pap smear versus sensitivity of uterine lavage in detection of tumor-derived TP53 mutations
- Specificity of pap smear versus specificity of uterine lavage in detection of tumor-derived TP53 mutations
|
25 |
Female |
18 Years and older (Adult, Older Adult) |
NCT03606486 |
10019
NCI-2018-01242
P30CA015704 |
|
November 16, 2018 |
September 15, 2019 |
September 15, 2019 |
July 30, 2018 |
February 15, 2019 |
|
- Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, United States
|
|
| 33 |
NCT02068794 |
Recruiting |
MV-NIS Infected Mesenchymal Stem Cells in Treating Patients With Recurrent Ovarian Cancer |
- Malignant Ovarian Brenner Tumor
- Ovarian Clear Cell Adenocarcinoma
- Ovarian Endometrioid Adenocarcinoma
- (and 7 more...)
|
- Other: Laboratory Biomarker Analysis
- Procedure: Mesenchymal Stem Cell Transplantation
- Biological: Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
|
Interventional
|
Phase 1
Phase 2 |
- Mayo Clinic
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- MTD, defined as the dose level below the lowest dose that induces dose-limiting toxicity in at least one-third of patients (at least 2 of a maximum of 6 new patients) (Phase I)
- Number and severity of adverse events (Phase I)
- Overall toxicity incidence (Phase I)
- (and 6 more...)
|
54 |
All |
18 Years and older (Adult, Older Adult) |
NCT02068794 |
MC1266
NCI-2014-00016
P30CA015083 |
|
March 2014 |
March 10, 2021 |
March 10, 2021 |
February 21, 2014 |
February 1, 2018 |
|
- Mayo Clinic
Rochester, Minnesota, United States
|
|
| 34 |
NCT00898781 |
Terminated |
Study of Circulating Cancer Cells in Patients With Metastatic Breast, Ovarian, Colon, or Pancreatic Cancer |
- Breast Cancer
- Colorectal Cancer
- Ovarian Cancer
- Pancreatic Cancer
|
|
Observational
|
|
- Mayo Clinic
- National Cancer Institute (NCI)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Frequency of circulating cancer cells (CTC)
- Variability in number of CTCs between patients with the same tumor type
- Correlation of the number of CTCs with extent of tumor burden as measured by tumor markers, imaging, and the number of metastatic sites and proliferation and apoptotic markers
|
80 |
All |
Child, Adult, Older Adult |
NCT00898781 |
CDR0000582085
P30CA015083
MC0744
07-006779 |
|
November 2007 |
April 2010 |
April 2010 |
May 12, 2009 |
July 19, 2011 |
|
- Mayo Clinic
Rochester, Minnesota, United States
|
|
| 35 |
NCT00620295 |
Completed |
Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors |
- Breast Cancer
- Colorectal Cancer
- Head and Neck Cancer
- (and 6 more...)
|
- Drug: bortezomib
- Drug: gemcitabine hydrochloride
|
Interventional
|
Phase 1 |
- Masonic Cancer Center, University of Minnesota
- Masonic Cancer Center, University of Minnesota
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose of bortezomib and gemcitabine
- Toxicity
- Disease response as measured by RECIST criteria
- Characterization of gemcitabine and metabolite pharmacokinetics (as part of co-enrollment in Population Pharmacokinetics and Pharmacogenetics of Gemcitabine in Adult Patients with Solid Tumors")
|
17 |
All |
70 Years and older (Older Adult) |
NCT00620295 |
CDR0000586510
UMN-2006LS040
UMN-X05227
x464 |
|
March 2007 |
February 2009 |
October 2009 |
February 21, 2008 |
November 29, 2017 |
|
- Masonic Cancer Center at University of Minnesota
Minneapolis, Minnesota, United States
|
|
| 36 |
NCT00436644 |
Completed
Has Results |
Lapatinib and Topotecan in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Did Not Respond to Cisplatin or Carboplatin |
- Ovarian Cancer
- Peritoneal Cavity Cancer
|
- Drug: Lapatinib
- Drug: Topotecan
|
Interventional
|
Phase 2 |
- Mayo Clinic
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response Rate (Complete Response (CR) or Partial Response (PR))
- Time to Progression
- Adverse Event Profile
- Overall Survival
|
18 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00436644 |
RC0661
P30CA015083
06-002426 |
|
March 2007 |
March 2009 |
November 2012 |
February 19, 2007 |
April 16, 2014 |
March 22, 2012 |
- Mayo Clinic Arizona
Scottsdale, Arizona, United States - Mayo Clinic in Jacksonville
Jacksonville, Florida, United States - Mayo Clinic Cancer Center
Rochester, Minnesota, United States
|
|
| 37 |
NCT01606241 |
Completed |
Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
- Recurrent Breast Carcinoma
- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- (and 24 more...)
|
- Drug: Cyclophosphamide
- Other: Laboratory Biomarker Analysis
- Biological: Multi-epitope Folate Receptor Alpha Peptide Vaccine
|
Interventional
|
Phase 1 |
- Mayo Clinic
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Proportion of patients who experience severe toxicities (grades 3-5 of the National Cancer Institute's Cancer Therapy Evaluation Program [CTEP] Common Terminology Criteria for Adverse Events, version 4.0)
- Disease-free survival
- FRa expression
- (and 2 more...)
|
24 |
Female |
18 Years and older (Adult, Older Adult) |
NCT01606241 |
MC1015
NCI-2012-00586
P30CA015083 |
|
July 24, 2012 |
September 25, 2014 |
March 3, 2018 |
May 25, 2012 |
September 18, 2018 |
|
- Mayo Clinic
Rochester, Minnesota, United States
|
|
| 38 |
NCT00083122 |
Completed
Has Results |
Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal Cancer |
- Recurrent Ovarian Epithelial Cancer
- Recurrent Primary Peritoneal Cavity Cancer
- Stage IIIA Ovarian Epithelial Cancer
- (and 7 more...)
|
- Drug: cisplatin
- Drug: alvocidib
- Drug: cisplatin/flavopiridol
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Proportion of Confirmed Tumor Responses Defined to be Either a Complete Response (CR) or Partial Response (PR)
- Overall Survival
- Time to Progression
|
45 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00083122 |
NCI-2009-00029
CDR0000363562
MC0261
5876
N01CM62205
P30CA015083 |
|
April 2004 |
July 2010 |
May 2012 |
May 17, 2004 |
May 21, 2014 |
May 14, 2013 |
- Mayo Clinic
Rochester, Minnesota, United States
|
|
| 39 |
NCT00017134 |
Terminated |
Fenretinide Followed by Surgery Compared With Surgery Alone in Preventing Ovarian Cancer in Patients at Increased Risk |
|
- Drug: fenretinide
- Procedure: conventional surgery
|
Interventional
|
Not Applicable |
- Gynecologic Oncology Group
- National Cancer Institute (NCI)
- Gynecologic Oncology Group
|
Other / NIH |
- Allocation: Randomized
- Primary Purpose: Prevention
|
|
71 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00017134 |
CDR0000068655
GOG-0190 |
|
September 2002 |
December 2006 |
|
May 7, 2003 |
June 10, 2013 |
|
- Jonsson Comprehensive Cancer Center at UCLA
Los Angeles, California, United States - Colorado Gynecologic Oncology Group P.C.
Aurora, Colorado, United States - Helen and Harry Gray Cancer Center at Hartford Hospital
Hartford, Connecticut, United States - (and 32 more...)
|
|
| 40 |
NCT00158145 |
Completed |
Assessing the Variability Over Time of Tobacco Carcinogen Biomarkers in Smokers - 2 |
|
|
Observational
|
|
- National Institute on Drug Abuse (NIDA)
|
NIH |
- Time Perspective: Prospective
|
|
72 |
All |
55 Years to 74 Years (Adult, Older Adult) |
NCT00158145 |
NIDA-13333-2
P50-13333-2
DPMC |
|
September 2005 |
April 2007 |
April 2007 |
September 12, 2005 |
January 10, 2017 |
|
- University of Minnesota
Minneapolis, Minnesota, United States
|
|
| 41 |
NCT00002819 |
Terminated |
Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer |
|
- Drug: carboplatin
- Drug: cyclophosphamide
- Drug: mitoxantrone hydrochloride
- (and 3 more...)
|
Interventional
|
Phase 3 |
- Gynecologic Oncology Group
- National Cancer Institute (NCI)
- Eastern Cooperative Oncology Group
- (and 3 more...)
|
Other / NIH |
- Allocation: Randomized
- Primary Purpose: Treatment
|
|
|
Female |
up to 65 Years (Child, Adult, Older Adult) |
NCT00002819 |
CDR0000064983
GOG-164
CLB-9791
E-G0164
SWOG-G0164 |
|
November 1996 |
February 2000 |
|
May 26, 2004 |
April 11, 2013 |
|
- Veterans Affairs Medical Center - Birmingham
Birmingham, Alabama, United States - University of California San Diego Cancer Center
La Jolla, California, United States - UCSF Cancer Center and Cancer Research Institute
San Francisco, California, United States - (and 61 more...)
|
|
| 42 |
NCT00086892 |
Completed |
Cetuximab and Carboplatin in Treating Patients With Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer |
- Ovarian Cancer
- Primary Peritoneal Cavity Cancer
|
- Biological: cetuximab
- Drug: carboplatin
|
Interventional
|
Phase 2 |
- Gynecologic Oncology Group
- National Cancer Institute (NCI)
- Bristol-Myers Squibb
- Gynecologic Oncology Group
|
Other / NIH / Industry |
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
|
Female |
18 Years and older (Adult, Older Adult) |
NCT00086892 |
GOG-0146P
BMS-CA225-019
CDR0000371712 |
|
June 2004 |
April 2006 |
|
July 12, 2004 |
February 14, 2014 |
|
- Comprehensive Cancer Center at University of Alabama at Birmingham
Birmingham, Alabama, United States - CCOP - Western Regional, Arizona
Phoenix, Arizona, United States - Jonsson Comprehensive Cancer Center at UCLA
Los Angeles, California, United States - (and 73 more...)
|
|
| 43 |
NCT02111941 |
Active, not recruiting |
Vaccine Therapy in Treating Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Following Surgery and Chemotherapy |
- Fallopian Tube Clear Cell Adenocarcinoma
- Fallopian Tube Endometrioid Tumor
- Fallopian Tube Mucinous Neoplasm
- (and 20 more...)
|
- Other: Laboratory Biomarker Analysis
- Biological: Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine
|
Interventional
|
Not Applicable |
- Mayo Clinic
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of dose-limiting toxicities (DLT), graded using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
- Overall survival (OS)
- Time to disease recurrence (TDR)
|
19 |
Female |
18 Years and older (Adult, Older Adult) |
NCT02111941 |
MC1361
NCI-2014-00713
P30CA015083 |
|
April 14, 2014 |
August 18, 2017 |
December 2019 |
April 11, 2014 |
February 19, 2019 |
|
- Mayo Clinic
Rochester, Minnesota, United States
|
|
| 44 |
NCT00003926 |
Terminated |
Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors |
- Brain and Central Nervous System Tumors
- Childhood Germ Cell Tumor
- Chordoma
- (and 6 more...)
|
- Drug: amifostine trihydrate
- Drug: busulfan
- Drug: filgrastim
- (and 3 more...)
|
Interventional
|
Phase 1 |
- Masonic Cancer Center, University of Minnesota
- Masonic Cancer Center, University of Minnesota
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
|
13 |
All |
1 Year to 45 Years (Child, Adult) |
NCT00003926 |
1997LS053
UMN-MT-9713
UMN-9712M00074 |
|
November 1998 |
August 2002 |
August 2003 |
May 2, 2003 |
November 29, 2017 |
|
- University of Minnesota Cancer Center
Minneapolis, Minnesota, United States
|
|
| 45 |
NCT01167712 |
Active, not recruiting
Has Results |
Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer |
- Fallopian Tube Endometrioid Adenocarcinoma
- Fallopian Tube Mucinous Adenocarcinoma
- Fallopian Tube Transitional Cell Carcinoma
- (and 27 more...)
|
- Biological: Bevacizumab
- Drug: Carboplatin
- Procedure: Computed Tomography
- (and 2 more...)
|
Interventional
|
Phase 3 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-Free Survival
- Median Duration of First Quartile Survival
- Quality of Life Score as Measured by Functional Assessment of Cancer Therapy-Ovary-Total Outcome Index (Fact-O TOI)
|
692 |
Female |
18 Years and older (Adult, Older Adult) |
NCT01167712 |
NCI-2011-03812
11-00374
GOG-0262/ACRIN 6695
ACRIN 6695
CDR0000681448
GOG-0262
U10CA180868
U10CA027469 |
|
September 27, 2010 |
December 1, 2015 |
|
July 22, 2010 |
January 3, 2019 |
January 23, 2018 |
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, United States - Providence Alaska Medical Center
Anchorage, Alaska, United States - (and 571 more...)
|
|
| 46 |
NCT00958698 |
Active, not recruiting |
Symptom Management in Patients With Recurrent or Persistent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer |
- Fallopian Tube Carcinoma
- Primary Peritoneal Carcinoma
- Psychological Impact of Cancer
- Recurrent Ovarian Carcinoma
|
- Other: Communication Intervention
- Other: Educational Intervention
- Other: Internet-Based Intervention
- (and 3 more...)
|
Interventional
|
Not Applicable |
- Gynecologic Oncology Group
- National Cancer Institute (NCI)
- Gynecologic Oncology Group
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Symptom severity, symptom-related distress, consequences, and control of symptoms as measured by the Symptom Representation Questionnaire
- Barriers to symptom management as measured by the Symptom Management Barriers Questionnaire
- Communication with health care providers and use of self-care strategies assessed by investigator-developed survey
- (and 3 more...)
|
485 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00958698 |
GOG-0259
NCI-2011-01950
CDR0000648729
U10CA101165 |
|
January 19, 2010 |
January 8, 2017 |
|
August 13, 2009 |
August 31, 2018 |
|
- Gynecologic Oncology Group of Arizona
Phoenix, Arizona, United States - Cedars Sinai Medical Center
Los Angeles, California, United States - UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, United States - (and 131 more...)
|
|
| 47 |
NCT00262990 |
Completed |
Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer |
- Ovarian Cancer
- Fallopian Tube Cancer
- Peritoneal Neoplasms
|
- Drug: EPO906 (Patupilone)
- Drug: doxorubicin
|
Interventional
|
Phase 3 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To show superiority of patupilone in overall survival compared to doxorubicin in taxane/platinum resistant patients with ovarian cancer
- To determine the duration of overall response in patients with complete response (CR) or partial response (PR) or stable disease (SD)
- To determine the progression-free survival (PFS) of patients treated with patupilone
- (and 5 more...)
|
829 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00262990 |
CEPO906A2303 |
|
November 2005 |
February 2010 |
|
December 7, 2005 |
May 4, 2012 |
|
- Alaska Cancer Research & Education Center
Anchorage, Alaska, United States - Northern Arizona Hematology & Oncology Associates
Flagstaff, Arizona, United States - Mayo Center for Women's Health
Scottsdale, Arizona, United States - (and 146 more...)
|
|
| 48 |
NCT00003523 |
Completed |
Aminocamptothecin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Cancer of the Peritoneum |
- Ovarian Cancer
- Primary Peritoneal Cavity Cancer
|
- Drug: aminocamptothecin colloidal dispersion
|
Interventional
|
Phase 2 |
- Gynecologic Oncology Group
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
Other / NIH |
- Primary Purpose: Treatment
|
|
|
Female |
13 Years and older (Child, Adult, Older Adult) |
NCT00003523 |
CDR0000066567
GOG-126I |
|
January 1999 |
|
October 2007 |
May 24, 2004 |
June 21, 2013 |
|
- University of Alabama Comprehensive Cancer Center
Birmingham, Alabama, United States - CCOP - Greater Phoenix
Phoenix, Arizona, United States - USC/Norris Comprehensive Cancer Center
Los Angeles, California, United States - (and 62 more...)
|
|
| 49 |
NCT00005836 |
Completed |
Oxaliplatin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Has Not Responded to Platinum- Based Chemotherapy |
- Ovarian Cancer
- Primary Peritoneal Cavity Cancer
|
|
Interventional
|
Phase 2 |
- Gynecologic Oncology Group
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
Other / NIH |
- Primary Purpose: Treatment
|
|
|
Female |
Child, Adult, Older Adult |
NCT00005836 |
CDR0000067851
GOG-126K |
|
February 2000 |
|
July 2004 |
April 29, 2003 |
June 21, 2013 |
|
- University of Alabama Comprehensive Cancer Center
Birmingham, Alabama, United States - CCOP - Greater Phoenix
Phoenix, Arizona, United States - USC/Norris Comprehensive Cancer Center
Los Angeles, California, United States - (and 71 more...)
|
|
| 50 |
NCT00381888 |
Completed
Has Results |
Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer |
- Cervical Cancer
- Endometrial Cancer
- Fallopian Tube Cancer
- (and 5 more...)
|
- Drug: fondaparinux sodium
|
Interventional
|
Phase 2 |
- Masonic Cancer Center, University of Minnesota
- Masonic Cancer Center, University of Minnesota
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Patients With Venous Thromboembolism at Week 4
- Number of Patients Who Achieved Thromboembolism Prophylaxis at Week 4.
|
44 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00381888 |
CDR0000503985
UMN-2006LS009
UMN-0603M82707 |
|
January 2007 |
January 2009 |
January 2009 |
September 28, 2006 |
December 28, 2017 |
January 27, 2010 |
- Masonic Cancer Center at University of Minnesota
Minneapolis, Minnesota, United States - Crozer-Chester Medical Center
Upland, Pennsylvania, United States
|
|
| 51 |
NCT01844986 |
Active, not recruiting |
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. |
- Newly Diagnosed
- Advanced Ovarian Cancer
- FIGO Stage III-IV
- (and 4 more...)
|
- Drug: Olaparib 300mg tablets
|
Interventional
|
Phase 3 |
- AstraZeneca
- Gynecologic Oncology Group (GOG)
- Myriad Genetic Laboratories, Inc.
- Merck Sharp & Dohme Corp.
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Progression Free Survival (PFS) by review of investigator-reported RECIST data
- Efficacy in patients following First Line Platinum Based Chemotherapy by assessment of overall survival.
- Change from baseline in Health-Related Quality of Life (HRQoL) as assessed by the individual domains of the trial outcome index (TOI) of the Functional Assessment of Cancer therapy - Ovarian (FACT-O)
- (and 8 more...)
|
451 |
Female |
18 Years to 130 Years (Adult, Older Adult) |
NCT01844986 |
D0818C00001 |
SOLO-1 |
August 26, 2013 |
May 17, 2018 |
June 6, 2023 |
May 3, 2013 |
December 10, 2018 |
|
- Clearview Cancer Institute
Huntsville, Alabama, United States - Providence Cancer Center
Anchorage, Alaska, United States - St. Joseph's Hospital & Medical Center
Phoenix, Arizona, United States - (and 174 more...)
|
|
| 52 |
NCT00003386 |
Terminated |
Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer |
|
- Biological: BCG vaccine
- Biological: autologous tumor cell vaccine
- Drug: carboplatin
- (and 5 more...)
|
Interventional
|
Phase 2 |
- Gynecologic Oncology Group
- National Cancer Institute (NCI)
- Gynecologic Oncology Group
|
Other / NIH |
- Primary Purpose: Treatment
|
|
|
Female |
18 Years and older (Adult, Older Adult) |
NCT00003386 |
CDR0000066382
GOG-9802 |
|
July 1999 |
April 2001 |
|
April 23, 2004 |
April 11, 2013 |
|
- University of Alabama Comprehensive Cancer Center
Birmingham, Alabama, United States - CCOP - Greater Phoenix
Phoenix, Arizona, United States - Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, United States - (and 57 more...)
|
|
| 53 |
NCT03146663 |
Recruiting |
NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer |
|
- Drug: NUC-1031 500 mg
- Drug: NUC-1031 750mg
|
Interventional
|
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective Response Rate (ORR)
- Change from baseline in tumor size
- Progression-Free Survival (per RECIST)
- (and 2 more...)
|
64 |
Female |
18 Years and older (Adult, Older Adult) |
NCT03146663 |
PRO-105
2016-003287-39 |
|
September 28, 2017 |
June 2019 |
June 2020 |
May 10, 2017 |
January 17, 2019 |
|
- Arizona Oncology Associates, PC - HAL
Scottsdale, Arizona, United States - Arizona Oncology Associates, PC - HOPE
Tucson, Arizona, United States - University of California
Orange, California, United States - (and 19 more...)
|
|
| 54 |
NCT00002717 |
Completed |
Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer |
- Ovarian Cancer
- Primary Peritoneal Cavity Cancer
|
- Drug: cisplatin
- Drug: paclitaxel
|
Interventional
|
Phase 3 |
- Gynecologic Oncology Group
- National Cancer Institute (NCI)
- Gynecologic Oncology Group
|
Other / NIH |
- Allocation: Randomized
- Primary Purpose: Treatment
|
|
324 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00002717 |
CDR0000064554
GOG-0162 |
|
March 1996 |
October 2007 |
|
June 22, 2004 |
May 27, 2013 |
|
- University of Alabama Comprehensive Cancer Center
Birmingham, Alabama, United States - USC/Norris Comprehensive Cancer Center
Los Angeles, California, United States - Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, United States - (and 49 more...)
|
|
| 55 |
NCT01372787 |
Active, not recruiting |
Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer |
- Anxiety
- Fatigue
- Nausea and Vomiting
- (and 20 more...)
|
- Procedure: Assessment of Therapy Complications
- Other: Medical Chart Review
- Other: Quality-of-Life Assessment
- Other: Questionnaire Administration
|
Observational
|
|
- Gynecologic Oncology Group
- National Cancer Institute (NCI)
- Gynecologic Oncology Group
|
Other / NIH |
|
- Prevalence and severity of patient-reported symptoms as measured by the NFOSI-18, the FACIT-F subscale, and the FACT/GOG-AD and NTX subscales
|
103 |
Female |
18 Years and older (Adult, Older Adult) |
NCT01372787 |
GOG-0267
NCI-2011-02547
CDR0000701477
U10CA101165 |
|
April 2011 |
January 2014 |
|
June 14, 2011 |
May 8, 2017 |
|
- University of Colorado Cancer Center - Anschutz Cancer Pavilion
Aurora, Colorado, United States - Hartford Hospital
Hartford, Connecticut, United States - Smilow Cancer Hospital Care Center at Saint Francis
Hartford, Connecticut, United States - (and 141 more...)
|
|
| 56 |
NCT02317705 |
Completed |
Phase 2 Study of OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer |
|
|
Interventional
|
Phase 2 |
- On Target Laboratories, LLC
- SynteractHCR
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
|
- Decision to increase dose and/or expand cohort will be based on the severity and confirmed by tumor-to-background ratio (TBR)
|
48 |
Female |
18 Years and older (Adult, Older Adult) |
NCT02317705 |
OTL-2014-OTL38-003 |
|
December 2014 |
November 2015 |
November 2015 |
December 16, 2014 |
July 26, 2016 |
|
- University of CA at Irvine Chao Cancer Center
Orange, California, United States - Moffitt Cancer Center
Tampa, Florida, United States - Mayo Clinic-Rochester
Rochester, Minnesota, United States - University of Pennsylvania
Philadelphia, Pennsylvania, United States
|
|
| 57 |
NCT00023699 |
Completed |
Gefitinib in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer |
- Ovarian Cancer
- Primary Peritoneal Cavity Cancer
|
|
Interventional
|
Phase 2 |
- Gynecologic Oncology Group
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
Other / NIH |
- Primary Purpose: Treatment
|
|
|
Female |
Child, Adult, Older Adult |
NCT00023699 |
CDR0000068852
GOG-0170C |
|
August 2001 |
|
May 2006 |
October 15, 2003 |
June 24, 2013 |
|
- University of Alabama at Birmingham Comprehensive Cancer Center
Birmingham, Alabama, United States - Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, United States - Community Hospital of Los Gatos
Los Gatos, California, United States - (and 50 more...)
|
|
| 58 |
NCT02311907 |
Completed
Has Results |
Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer |
- Chemotherapeutic Agent Toxicity
- Neuropathy
- Neurotoxicity Syndrome
- (and 13 more...)
|
- Drug: Carboplatin
- Drug: Glutathione
- Other: Laboratory Biomarker Analysis
- (and 3 more...)
|
Interventional
|
Phase 3 |
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
- Alliance for Clinical Trials in Oncology
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Supportive Care
|
- Paclitaxel/Carboplatin (PC) Induced Peripheral Neuropathy as Assessed by EORTC QLQ-CIPN20 (European Organization for Research and Treatment of Cancer (EORTC), Quality of Life (QLQ), Chemotherapy Induced Peripheral Neuropathy 20 (CIPN20)).
- Recurrence-free Survival (for Patients Without Clinical Evidence of Disease)
- Change in Patient Reported Quality of Life as Assessed by Functional Assessment of Cancer Therapy-Ovarian (FACT-O) and Patient Daily-symptom Questionnaires Over Time.
- (and 6 more...)
|
195 |
All |
18 Years and older (Adult, Older Adult) |
NCT02311907 |
N08CA
NCI-2011-01965
CDR0000654097
U10CA037404 |
|
December 2009 |
August 2012 |
August 2012 |
December 9, 2014 |
February 23, 2017 |
February 23, 2017 |
- Providence Hospital
Mobile, Alabama, United States - Fairbanks Memorial Hospital
Fairbanks, Alaska, United States - Mayo Clinic in Arizona
Scottsdale, Arizona, United States - (and 387 more...)
|
|
| 59 |
NCT01565421 |
Withdrawn |
Efficacy Study of Maintenance Therapy for Ovarian Cancer Patients |
- Cancer
- Ovarian Cancer
- Solid Tumor
|
- Drug: IT-101
- Drug: 5% Dextrose (Placebo)
|
Interventional
|
Phase 2 |
- NewLink Genetics Corporation
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- To Compare the proportion of patients without evidence of disease progression at 30 weeks following randomization between IT-101 at 12 mg/m2/dose or 15 mg/m2/dose to a placebo infusion treatment administered every other week.
- Comparison of adverse drug experiences between each treatment
- Compare the frequency of drug-related toxicities between each treatment arm
- Compare Quality of Life (QOL, patient-reported) measures (FACT-O, FOSI) between treatment arms.
|
0 |
Female |
18 Years to 78 Years (Adult, Older Adult) |
NCT01565421 |
ID OVAR0801 |
|
September 2008 |
October 2009 |
May 2010 |
March 28, 2012 |
April 20, 2017 |
|
- Decatur Memorial Hospital, Clinical Research Department/ Cancer Care Specialists of Illinois
Decatur, Illinois, United States - University of Minnesota Medical Center
Minneapolis, Minnesota, United States - Schwartz Gynecologic Onclology, PLLC
Brightwaters, New York, United States - (and 4 more...)
|
|
| 60 |
NCT02042430 |
Active, not recruiting |
Epacadostat Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
- Stage III Fallopian Tube Cancer AJCC v7
- Stage III Ovarian Cancer AJCC v6 and v7
- Stage III Primary Peritoneal Cancer AJCC v7
- (and 12 more...)
|
- Drug: Epacadostat
- Other: Laboratory Biomarker Analysis
- Procedure: Therapeutic Conventional Surgery
|
Interventional
|
Early Phase 1 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of participants with an increase in CD8+ T cells
- Change in number and character of tumor infiltrating lymphocytes
- Change in gene signatures as assessed by microarray analysis
- (and 8 more...)
|
17 |
Female |
19 Years and older (Adult, Older Adult) |
NCT02042430 |
NCI-2013-02483
CITN-05 OVARIAN IDO
ICD 10033159
ICD 10016180
ICD 10026669
CITN-05
P30CA015704
U01CA154967 |
|
December 31, 2013 |
March 31, 2016 |
|
January 22, 2014 |
February 15, 2019 |
|
- University of Minnesota/Masonic Cancer Center
Minneapolis, Minnesota, United States - Roswell Park Cancer Institute
Buffalo, New York, United States
|
|
| 61 |
NCT00753740 |
Withdrawn |
Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients. |
- Cancer
- Ovarian Cancer
- Solid Tumor
|
- Drug: IT-101 (12mg/m2/dose)
- Drug: IT-101 (15mg/m2/dose)
- Drug: 5% Dextrose (Placebo)
|
Interventional
|
Phase 2 |
- NewLink Genetics Corporation
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- To Compare the proportion of patients without evidence of disease progression at 30 weeks following randomization between IT-101 at 12 mg/m2/dose or 15 mg/m2/dose to a placebo infusion treatment administered every other week.
- Comparison of adverse drug experiences between each treatment
- Compare the frequency of drug-related toxicities between each treatment arm
- Compare Quality of Life (QOL, patient-reported) measures (FACT-O, FOSI) between treatment arms.
|
0 |
Female |
18 Years to 78 Years (Adult, Older Adult) |
NCT00753740 |
OVAR0801 |
|
September 2008 |
October 2009 |
May 2010 |
September 16, 2008 |
April 19, 2017 |
|
- Decatur Memorial Hospital, Clinical Research Department/ Cancer Care Specialists of Illinois
Decatur, Illinois, United States - University of Minnesota Medical Center
Minneapolis, Minnesota, United States - Schwartz Gynecologic Onclology, PLLC
Brightwaters, New York, United States - (and 4 more...)
|
|
| 62 |
NCT01666444 |
Unknown † |
VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer |
- Epithelial Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Cancer
|
- Drug: pegylated liposomal doxorubicin (PLD)
- Drug: VTX-2337
- Drug: Placebo
|
Interventional
|
Phase 2 |
- VentiRx Pharmaceuticals Inc.
- Gynecologic Oncology Group
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Overall survival (OS) of patients treated with VTX-2337 + PLD versus those treated with PLD alone
- Progression-free survival (PFS) of patients treated with VTX-2337 + PLD versus those treated with PLD alone using Immune-Related Response Evaluation Criteria In Solid Tumors (irRECIST).
- Frequency and severity of drug-related adverse events (AEs) of patients treated with VTX-2337 + PLD versus those treated with PLD alone.
|
290 |
Female |
18 Years and older (Adult, Older Adult) |
NCT01666444 |
GOG-3003 |
|
October 2012 |
October 2016 |
October 2016 |
August 16, 2012 |
July 22, 2016 |
|
- St. Joseph's Hospital and Medical Center
Phoenix, Arizona, United States - Winthrop P. Rockefeller Cancer Institute - University of Arkansas
Little Rock, Arkansas, United States - Providence Saint Joseph Medical Center
Burbank, California, United States - (and 133 more...)
|
|
| 63 |
NCT03038100 |
Recruiting |
A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
- Ovarian Cancer
- Fallopian Tube Cancer
- Peritoneal Neoplasms
|
- Drug: Paclitaxel
- Drug: Carboplatin
- Drug: Atezolizumab
- (and 2 more...)
|
Interventional
|
Phase 3 |
- Hoffmann-La Roche
- GOG Foundation
- European Network of Gynaecological Oncological Trial Groups (ENGOT)
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Progression-Free Survival (PFS) Assessed by Investigator as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) - Intent-to-Treat (ITT) Population
- PFS Assessed by Investigator as Per RECIST v1.1 - Programmed Death−Ligand 1 (PD-L1)−Positive Subpopulation
- Overall Survival - ITT Population
- (and 10 more...)
|
1300 |
Female |
18 Years and older (Adult, Older Adult) |
NCT03038100 |
YO39523
2016-003472-52 |
IMagyn050 |
March 8, 2017 |
April 1, 2020 |
December 1, 2021 |
January 31, 2017 |
February 19, 2019 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States - St. Joseph'S Hospital & Medical Center
Phoenix, Arizona, United States - Mayo Clinic Arizona
Scottsdale, Arizona, United States - (and 377 more...)
|
|
| 64 |
NCT00003322 |
Completed |
Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer |
- Ovarian Cancer
- Primary Peritoneal Cavity Cancer
|
- Drug: cisplatin
- Drug: paclitaxel
- Procedure: quality-of-life assessment
|
Interventional
|
Phase 3 |
- Gynecologic Oncology Group
- National Cancer Institute (NCI)
- Gynecologic Oncology Group
|
Other / NIH |
- Allocation: Randomized
- Primary Purpose: Treatment
|
|
384 |
Female |
Child, Adult, Older Adult |
NCT00003322 |
CDR0000066273
GOG-0172 |
|
March 1998 |
January 2006 |
|
May 21, 2004 |
May 27, 2013 |
|
- University of Alabama Comprehensive Cancer Center
Birmingham, Alabama, United States - CCOP - Greater Phoenix
Phoenix, Arizona, United States - USC/Norris Comprehensive Cancer Center
Los Angeles, California, United States - (and 64 more...)
|
|
| 65 |
NCT01469793 |
Completed |
A Study of DMOT4039A in Participants With Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer |
|
|
Interventional
|
Phase 1 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose (MTD) of DMOT4039A
- Number of Participants With Dose-Limiting Toxicities (DLTs)
- Recommended Phase 2 Dose (RP2D) of DMOT4039A
- (and 17 more...)
|
71 |
All |
18 Years and older (Adult, Older Adult) |
NCT01469793 |
DMO4993g
GP27896
2011-002713-10 |
|
November 2011 |
December 2015 |
December 2015 |
November 10, 2011 |
January 10, 2017 |
|
- Phoenix, Arizona, United States
- Aurora, Colorado, United States
- Jacksonville, Florida, United States
- (and 3 more...)
|
|
| 66 |
NCT03029585 |
Active, not recruiting |
Phase II Study of Intraperitoneal NanoPac® in Patients With Ovarian Cancer |
|
- Drug: NanoPac® 100 mg/m2
- Drug: NanoPac® 200 mg/m2
- Drug: NanoPac® 300 mg/m2
- (and 2 more...)
|
Interventional
|
Phase 2 |
- NanOlogy, LLC
- US Biotest, Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Treatment-emergent adverse events
- Progression-free survival at 12 months
- Maximum Plasma Concentration of Paclitaxel (Cmax)
|
61 |
Female |
18 Years and older (Adult, Older Adult) |
NCT03029585 |
NANOPAC-2016-01 |
|
April 19, 2017 |
September 2019 |
September 2019 |
January 24, 2017 |
January 17, 2019 |
|
- University of Chicago
Chicago, Illinois, United States - Greater Baltimore Medical Center
Baltimore, Maryland, United States - University of Minnesota
Minneapolis, Minnesota, United States - (and 4 more...)
|
|
| 67 |
NCT00023907 |
Terminated |
Paclitaxel in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer |
- Ovarian Cancer
- Primary Peritoneal Cavity Cancer
|
|
Interventional
|
Phase 2 |
- Gynecologic Oncology Group
- National Cancer Institute (NCI)
- Gynecologic Oncology Group
|
Other / NIH |
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
|
Female |
Child, Adult, Older Adult |
NCT00023907 |
CDR0000068875
GOG-0126N |
|
July 2001 |
April 2006 |
|
July 9, 2003 |
April 11, 2013 |
|
- CCOP - Western Regional, Arizona
Phoenix, Arizona, United States - Women's Cancer Center at Community Hospital of Los Gatos
Los Gatos, California, United States - Chao Family Comprehensive Cancer Center at University of California Irvine Cancer Center
Orange, California, United States - (and 41 more...)
|
|
| 68 |
NCT00445887 |
Completed
Has Results |
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer |
|
- Other: Laboratory Biomarker Analysis
- Drug: Levonorgestrel
- Other: Placebo
|
Interventional
|
Phase 2 |
- Gynecologic Oncology Group
- National Cancer Institute (NCI)
- Gynecologic Oncology Group
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Prevention
|
- Median Proportion Cells That Are Apoptotic in Epithelial Ovarian Tissue
- Number of Participants With Adverse Events According to Grade as Determined by NCI CTCAE v.3.0
- Proportion of Proliferation as Measured by Ki-67
- Patients With High Expression of Transforming Growth Factor-beta 1
|
64 |
Female |
30 Years and older (Adult, Older Adult) |
NCT00445887 |
GOG-0214
NCI-2009-00588
CDR0000532268
U10CA101165 |
|
March 2008 |
December 2012 |
|
March 9, 2007 |
January 11, 2018 |
January 11, 2018 |
- City of Hope Comprehensive Cancer Center
Duarte, California, United States - UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California, United States - University of California San Diego
San Diego, California, United States - (and 51 more...)
|
|
| 69 |
NCT00004037 |
Terminated |
Docetaxel in Treating Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Cancer |
- Ovarian Cancer
- Primary Peritoneal Cavity Cancer
|
|
Interventional
|
Phase 2 |
- Gynecologic Oncology Group
- National Cancer Institute (NCI)
- Gynecologic Oncology Group
|
Other / NIH |
- Primary Purpose: Treatment
|
|
|
Female |
18 Years and older (Adult, Older Adult) |
NCT00004037 |
CDR0000066369
GOG-126J |
|
June 1998 |
April 2003 |
|
June 25, 2003 |
April 11, 2013 |
|
- University of Alabama Comprehensive Cancer Center
Birmingham, Alabama, United States - CCOP - Greater Phoenix
Phoenix, Arizona, United States - USC/Norris Comprehensive Cancer Center
Los Angeles, California, United States - (and 64 more...)
|
|
| 70 |
NCT03522246 |
Recruiting |
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy |
- Epithelial Ovarian Cancer
- Primary Peritoneal
- Fallopian Tube Cancer
- (and 4 more...)
|
- Drug: Rucaparib
- Drug: Nivolumab
- Drug: Placebo Oral Tablet
- Drug: Placebo IV Infusion
|
Interventional
|
Phase 3 |
- Clovis Oncology, Inc.
- Bristol-Myers Squibb
- Gynecologic Oncology Group
- (and 3 more...)
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Investigator assessed Progression-free survival (PFS)
- Blinded independent central review (BICR) PFS
- Overall Survival (OS)
- (and 5 more...)
|
1012 |
Female |
18 Years and older (Adult, Older Adult) |
NCT03522246 |
CO-338-087/GOG-3020/ENGOT-ov45 |
ATHENA |
May 14, 2018 |
December 30, 2024 |
December 30, 2030 |
May 11, 2018 |
February 7, 2019 |
|
- Arizona Oncology Associates, PC - HAL
Phoenix, Arizona, United States - Arizona Oncology Associates, PC - HOPE
Tucson, Arizona, United States - The University of Arizona Cancer Center
Tucson, Arizona, United States - (and 87 more...)
|
|
| 71 |
NCT00003644 |
Completed |
Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer |
|
- Drug: carboplatin
- Drug: paclitaxel
|
Interventional
|
Phase 3 |
- Gynecologic Oncology Group
- National Cancer Institute (NCI)
- Southwest Oncology Group
- Gynecologic Oncology Group
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Recurrence-free interval
- Overall survival
- Frequency and severity of adverse events
|
571 |
Female |
up to 120 Years (Child, Adult, Older Adult) |
NCT00003644 |
GOG-0175
NCI-2012-02291
SWOG-G0175 |
|
October 1998 |
March 2010 |
|
January 27, 2003 |
March 21, 2016 |
|
- University of Alabama at Birmingham Comprehensive Cancer Center
Birmingham, Alabama, United States - Banner Thunderbird Medical Center
Glendale, Arizona, United States - Banner Good Samaritan Medical Center
Phoenix, Arizona, United States - (and 148 more...)
|
|
| 72 |
NCT00951496 |
Active, not recruiting
Has Results |
Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer |
- Ovarian Brenner Tumor
- Ovarian Clear Cell Cystadenocarcinoma
- Ovarian Endometrioid Adenocarcinoma
- (and 19 more...)
|
- Biological: Bevacizumab
- Drug: Carboplatin
- Drug: Cisplatin
- (and 3 more...)
|
Interventional
|
Phase 3 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Median Progression-free Survival
- Patients With Adverse Events by Treatment Group, as Defined by NCI CTCAE (Common Terminology Criteria for Adverse Events Version 3.0) Version 3.0
- Overall Survival
- (and 4 more...)
|
1560 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00951496 |
NCI-2011-01956
09-0724
CDR0000650601
GOG-0252
U10CA180868
U10CA027469 |
|
August 11, 2009 |
January 11, 2016 |
|
August 4, 2009 |
February 15, 2019 |
May 18, 2018 |
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, United States - Providence Alaska Medical Center
Anchorage, Alaska, United States - (and 502 more...)
|
|
| 73 |
NCT01847274 |
Completed |
A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer |
- Platinum Sensitive Ovarian Cancer
|
- Drug: Active comparator: Niraparib
- Drug: placebo
|
Interventional
|
Phase 3 |
- Tesaro, Inc.
- European Network of Gynaecological Oncological Trial Groups (ENGOT)
- Myriad Genetics, Inc.
- (and 4 more...)
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Progression free survival of ovarian cancer patients
- Patient Reported Outcomes
- Progression Free Survival Two
- (and 5 more...)
|
597 |
Female |
18 Years and older (Adult, Older Adult) |
NCT01847274 |
PR-30-5011-C |
|
June 2013 |
June 2016 |
June 2016 |
May 6, 2013 |
December 13, 2016 |
|
- Phoenix, Arizona, United States
- Tucson, Arizona, United States
- La Jolla, California, United States
- (and 105 more...)
|
|
| 74 |
NCT00287885 |
Completed |
Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancer |
- Cervical Cancer
- Endometrial Cancer
- Fallopian Tube Cancer
- (and 5 more...)
|
|
Interventional
|
Phase 1 |
- Masonic Cancer Center, University of Minnesota
- Masonic Cancer Center, University of Minnesota
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose
- Response to Treatment
- Pharmacokinetics
|
18 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00287885 |
2003LS034
UMN-WCC-35
0307M50626 |
|
March 2004 |
December 2008 |
December 2008 |
February 7, 2006 |
November 29, 2017 |
|
|
|
| 75 |
NCT03602586 |
Recruiting |
Pembrolizumab and Epacadostat in Treating Patients With Recurrent, Persistent, or Progressive Ovarian Clear Cell Carcinoma |
- Malignant Ovarian Clear Cell Tumor
- Recurrent Ovarian Carcinoma
|
- Drug: Epacadostat
- Biological: Pembrolizumab
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Complete or partial objective tumor response
- Nature and degree of adverse events
- Progression-free survival (PFS)
- Overall survival (OS)
|
23 |
Female |
18 Years and older (Adult, Older Adult) |
NCT03602586 |
NCI-2018-01561
NRG-GY016
U10CA180868 |
|
September 28, 2018 |
April 30, 2021 |
April 30, 2021 |
July 27, 2018 |
February 15, 2019 |
|
- Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - (and 244 more...)
|
|
| 76 |
NCT00020696 |
Completed |
Tirapazamine Plus Cisplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer |
- Ovarian Cancer
- Primary Peritoneal Cavity Cancer
|
- Drug: cisplatin
- Drug: tirapazamine
|
Interventional
|
Phase 2 |
- Gynecologic Oncology Group
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
Other / NIH |
- Primary Purpose: Treatment
|
|
|
Female |
Child, Adult, Older Adult |
NCT00020696 |
CDR0000068705
GOG-0146M |
|
June 2001 |
April 2006 |
|
February 4, 2004 |
January 10, 2012 |
|
- University of Alabama at Birmingham Comprehensive Cancer Center
Birmingham, Alabama, United States - Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, United States - Community Hospital of Los Gatos
Los Gatos, California, United States - (and 51 more...)
|
|
| 77 |
NCT00006812 |
Terminated |
Capecitabine in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cavity Cancer |
- Ovarian Cancer
- Primary Peritoneal Cavity Cancer
|
|
Interventional
|
Phase 2 |
- Gynecologic Oncology Group
- National Cancer Institute (NCI)
- Gynecologic Oncology Group
|
Other / NIH |
- Primary Purpose: Treatment
|
|
|
Female |
Child, Adult, Older Adult |
NCT00006812 |
CDR0000068330
GOG-0146L |
|
March 2001 |
July 2005 |
|
March 17, 2004 |
April 11, 2013 |
|
- University of Alabama at Birmingham Comprehensive Cancer Center
Birmingham, Alabama, United States - USC/Norris Comprehensive Cancer Center and Hospital
Los Angeles, California, United States - Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, United States - (and 28 more...)
|
|
| 78 |
NCT03330405 |
Recruiting |
Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors |
- Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors
|
- Drug: Avelumab Phase 1b
- Drug: Talazoparib Phase 1b
- Drug: Avelumab Phase 2
- Drug: Talazoparib Phase 2
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Dose Limiting Toxicity (DLT)
- Overall Response (OR)
- Serum concentrations of avelumab
- (and 15 more...)
|
242 |
All |
18 Years and older (Adult, Older Adult) |
NCT03330405 |
B9991025
2017-001509-33
JAVELIN PARP MEDLEY |
|
October 19, 2017 |
March 28, 2020 |
March 28, 2020 |
November 6, 2017 |
February 18, 2019 |
|
- Highlands Oncology Group
Fayetteville, Arkansas, United States - Highlands Oncology Group
Rogers, Arkansas, United States - Freidenrich Center for Translational Research (CTRU)
Palo Alto, California, United States - (and 49 more...)
|
|
| 79 |
NCT02839707 |
Recruiting |
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
- Fallopian Tube Clear Cell Adenocarcinoma
- Fallopian Tube Endometrioid Adenocarcinoma
- Fallopian Tube Undifferentiated Carcinoma
- (and 10 more...)
|
- Drug: Atezolizumab
- Biological: Bevacizumab
- Other: Laboratory Biomarker Analysis
- (and 2 more...)
|
Interventional
|
Phase 2
Phase 3 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of dose limiting toxicities (DLT) of experimental regimens graded using Common Terminology Criteria for Adverse Events (CTCAE) version (v.) 4.0 (CTCAE version 5.0 will be used beginning April 1, 2018)
- Progression free survival (PFS) assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version (v.) 1.1 criteria (Phase II)
- Overall survival (OS) (Phase III)
- (and 10 more...)
|
488 |
Female |
18 Years and older (Adult, Older Adult) |
NCT02839707 |
NCI-2016-01081
NRG-GY009
U10CA180868
UG1CA189867 |
|
May 12, 2017 |
June 30, 2023 |
June 30, 2023 |
July 21, 2016 |
February 15, 2019 |
|
- Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - (and 729 more...)
|
|
| 80 |
NCT00093496 |
Completed
Has Results |
Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer |
- Primary Peritoneal Cavity Cancer
- Recurrent Ovarian Epithelial Cancer
- Stage III Ovarian Epithelial Cancer
- Stage IV Ovarian Epithelial Cancer
|
- Drug: gemcitabine hydrochloride
- Drug: tanespimycin
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Proportion of Patients Who Experience a Confirmed Response According to Modified RECIST Criteria.
- Times to Progression
- Overall Survival
- Toxicity
|
29 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00093496 |
NCI-2009-00052
CDR0000388036
NCI-6307
MAYO-MC0362
MC0362
6307
P30CA015083
N01CM62205 |
|
October 2007 |
April 2010 |
March 2012 |
October 8, 2004 |
May 20, 2014 |
July 10, 2013 |
- Mayo Clinic
Rochester, Minnesota, United States
|
|
| 81 |
NCT00002568 |
Completed |
Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer |
|
- Drug: cisplatin
- Drug: paclitaxel
- Procedure: conventional surgery
|
Interventional
|
Phase 3 |
- Gynecologic Oncology Group
- National Cancer Institute (NCI)
- Gynecologic Oncology Group
|
Other / NIH |
- Allocation: Randomized
- Primary Purpose: Treatment
|
|
470 |
Female |
Child, Adult, Older Adult |
NCT00002568 |
CDR0000063600
GOG-152 |
|
June 1994 |
December 2004 |
|
May 5, 2004 |
July 9, 2013 |
|
- University of Alabama Comprehensive Cancer Center
Birmingham, Alabama, United States - CCOP - Greater Phoenix
Phoenix, Arizona, United States - USC/Norris Comprehensive Cancer Center
Los Angeles, California, United States - (and 52 more...)
|
|
| 82 |
NCT00179712 |
Completed |
Study of Lenalidomide With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma |
|
- Drug: CC-5013
- Drug: topotecan
|
Interventional
|
Phase 1
Phase 2 |
- Celgene Corporation
- Prologue Research International
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Factorial Assignment
- Masking: None (Open Label)
|
- Phase I-To determine the MTD and evaluate the safety profile of oral lenalidomide and topotecan
- Phase II-To explore the anti-tumor activity based on objective response rate (CR + PR) of the combination of oral lenalidomide and topotecan
- Phase I-To explore the anti-tumor activity based on response of the combination of lenalidomide and topotecan.
- Phase II-To explore the safety profile of the combination of lenalidomide and topotecan
|
60 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00179712 |
CC-5013-OVRY-002 |
|
April 2005 |
|
November 2006 |
September 16, 2005 |
December 1, 2016 |
|
- Medical College of GeorgiaDept of OBGYN
Augusta, Georgia, United States - University of MinnesotaObstetrics & Gynecology, MMC
Minneapolis, Minnesota, United States - Ohio State University
Columbus, Ohio, United States
|
|
| 83 |
NCT00748657 |
Completed
Has Results |
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary |
- Malignant Ovarian Epithelial Tumor
- Ovarian Granulosa Cell Tumor
- Ovarian Gynandroblastoma
- (and 5 more...)
|
- Biological: Bevacizumab
- Other: Laboratory Biomarker Analysis
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Tumor Response
- Progression-free Survival
- Overall Survival
- Number of Participants With Episodes and Grade of Adverse Events as Assessed by Common Terminology for Adverse Events Version 3.0
|
36 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00748657 |
NCI-2009-00611
CDR0000613531
GOG-0251
U10CA180868
U10CA027469 |
|
September 22, 2008 |
January 31, 2013 |
January 31, 2013 |
September 8, 2008 |
October 17, 2018 |
June 10, 2015 |
- Los Angeles County-USC Medical Center
Los Angeles, California, United States - USC / Norris Comprehensive Cancer Center
Los Angeles, California, United States - University of Colorado Hospital
Aurora, Colorado, United States - (and 33 more...)
|
|
| 84 |
NCT01704651 |
Completed
Has Results |
Accelerating Gastrointestinal Recovery |
- Ovarian Cancer
- Fallopian Tube Cancer
- Peritoneal Cancer
|
- Drug: Alvimopan
- Drug: Placebo
|
Interventional
|
Phase 3 |
- Jamie N. Bakkum-Gamez
- Cubist Pharmaceuticals LLC
- Mayo Clinic
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Prevention
|
- Postoperative Length of Hospital Stay
- Postoperative Ileus Incidence
|
146 |
Female |
18 Years and older (Adult, Older Adult) |
NCT01704651 |
12-004082 |
|
January 2013 |
August 2015 |
October 2015 |
October 11, 2012 |
October 24, 2016 |
October 24, 2016 |
- Mayo Clinic
Rochester, Minnesota, United States
|
|
| 85 |
NCT00005029 |
Terminated |
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer |
- Ovarian Cancer
- Primary Peritoneal Cavity Cancer
|
- Drug: topotecan hydrochloride
|
Interventional
|
Phase 2 |
- Gynecologic Oncology Group
- National Cancer Institute (NCI)
- Gynecologic Oncology Group
|
Other / NIH |
- Primary Purpose: Treatment
|
|
|
Female |
up to 120 Years (Child, Adult, Older Adult) |
NCT00005029 |
CDR0000067550
GOG-0146K |
|
February 2000 |
January 2004 |
|
July 19, 2004 |
April 12, 2018 |
|
- University of Alabama Comprehensive Cancer Center
Birmingham, Alabama, United States - CCOP - Greater Phoenix
Phoenix, Arizona, United States - USC/Norris Comprehensive Cancer Center
Los Angeles, California, United States - (and 71 more...)
|
|
| 86 |
NCT00002478 |
Terminated |
Etoposide in Treating Patients With Advanced Ovarian or Cervical Cancer |
- Cervical Cancer
- Ovarian Cancer
|
|
Interventional
|
Phase 2 |
- Gynecologic Oncology Group
- National Cancer Institute (NCI)
- Gynecologic Oncology Group
|
Other / NIH |
- Primary Purpose: Treatment
|
|
|
Female |
Child, Adult, Older Adult |
NCT00002478 |
CDR0000077078
GOG-26LL |
|
June 1993 |
October 2003 |
|
June 9, 2004 |
June 10, 2013 |
|
- University of Alabama Comprehensive Cancer Center
Birmingham, Alabama, United States - USC/Norris Comprehensive Cancer Center
Los Angeles, California, United States - Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, United States - (and 44 more...)
|
|
| 87 |
NCT00017303 |
Unknown † |
Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer |
- Ovarian Cancer
- Primary Peritoneal Cavity Cancer
|
- Drug: carboplatin
- Drug: oglufanide disodium
- Drug: paclitaxel
- Procedure: conventional surgery
|
Interventional
|
Phase 2 |
- Cytran
- National Cancer Institute (NCI)
|
Industry |
- Primary Purpose: Treatment
|
|
|
Female |
18 Years and older (Adult, Older Adult) |
NCT00017303 |
CDR0000068674
CYTRAN-IM862-302
FHCRC-5156 |
|
January 2001 |
|
|
February 27, 2004 |
November 6, 2013 |
|
- Comprehensive Cancer Center
Glendale, California, United States - Community Hospital of Los Gatos
Los Gatos, California, United States - Stanford University Medical Center
Stanford, California, United States - (and 16 more...)
|
|
| 88 |
NCT02657928 |
Active, not recruiting |
Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer |
- Estrogen Receptor Positive
- Postmenopausal
- Recurrent Fallopian Tube Carcinoma
- (and 3 more...)
|
- Other: Laboratory Biomarker Analysis
- Drug: Letrozole
- Drug: Ribociclib
|
Interventional
|
Phase 2 |
- Mayo Clinic
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Proportion of patients alive and progression-free at 12 weeks
- CA-125 response, defined as a 50% or greater reduction in baseline CA-125
- Confirmed response rate (complete response or partial response) using Response Evaluation Criteria in Solid Tumors version 1.1
- (and 3 more...)
|
40 |
Female |
18 Years and older (Adult, Older Adult) |
NCT02657928 |
MC1561
NCI-2015-02181
P30CA015083 |
|
July 8, 2016 |
June 2021 |
July 2021 |
January 18, 2016 |
May 18, 2018 |
|
- Mayo Clinic in Arizona
Scottsdale, Arizona, United States - Mayo Clinic in Florida
Jacksonville, Florida, United States - Mayo Clinic
Rochester, Minnesota, United States
|
|
| 89 |
NCT00002538 |
Completed |
Laparoscopic Staging in Patients With Ovarian, Fallopian Tube, or Other Primary Abdominal Cancers |
- Fallopian Tube Cancer
- Ovarian Cancer
- Primary Peritoneal Cavity Cancer
|
- Procedure: laparoscopic surgery
|
Interventional
|
Phase 2 |
- Gynecologic Oncology Group
- National Cancer Institute (NCI)
- Gynecologic Oncology Group
|
Other / NIH |
- Primary Purpose: Treatment
|
|
|
Female |
18 Years and older (Adult, Older Adult) |
NCT00002538 |
GOG-9302
CDR0000078530 |
|
September 1993 |
March 2010 |
|
June 10, 2004 |
August 20, 2013 |
|
- USC/Norris Comprehensive Cancer Center
Los Angeles, California, United States - Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, United States - Women's Cancer Center
Palo Alto, California, United States - (and 8 more...)
|
|
| 90 |
NCT00288275 |
Terminated |
Correlation of the Chemoresponse Assay With PFS in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer |
- Ovarian Cancer
- Fallopian Tube Cancer
- Peritoneal Neoplasms
|
|
Observational
|
|
|
Industry |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Progression Free Survival
- Tumor Response
|
256 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00288275 |
PT-301 |
|
July 2004 |
|
October 2012 |
February 7, 2006 |
October 5, 2012 |
|
- University of California
Irvine, California, United States - Kaiser Permanente
Los Angeles, California, United States - Yale University Medical Center
New Haven, Connecticut, United States - (and 33 more...)
|
|
| 91 |
NCT00565851 |
Active, not recruiting |
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer |
- Clear Cell Adenocarcinoma
- Fallopian Tube Clear Cell Adenocarcinoma
- Fallopian Tube Endometrioid Adenocarcinoma
- (and 15 more...)
|
- Biological: Bevacizumab
- Drug: Carboplatin
- Drug: Docetaxel
- (and 4 more...)
|
Interventional
|
Phase 3 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To determine if surgical secondary cytoreduction in addition to adjuvant chemotherapy increases the duration of overall survival in patients with recurrent platinum sensitive epithelial ovarian cancer, peritoneal primary or fallopian tube cancer
- To determine if the addition of bevacizumab increases the duration of overall survival relative to second-line paclitaxel and carboplatin alone in patients with recurrent platinum sensitive epithelial ovarian, peritoneal primary or fallopian tube cancer
- Progression-free survival
- (and 3 more...)
|
1038 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00565851 |
NCI-2009-00587
CDR0000546714
GOG-0213
09-0205
U10CA180868
U10CA027469 |
|
December 6, 2007 |
March 15, 2019 |
|
November 30, 2007 |
February 19, 2019 |
|
- Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - (and 717 more...)
|
|
| 92 |
NCT00003892 |
Completed |
ISIS 5132 in Treating Patients With Metastatic or Recurrent Ovarian Cancer |
|
|
Interventional
|
Phase 2 |
- NCIC Clinical Trials Group
- Canadian Cancer Trials Group
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective and duration of response
- Toxicity
|
22 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00003892 |
I116
CAN-NCIC-IND116
CDR0000067061 |
|
February 1999 |
October 2000 |
September 2008 |
August 5, 2004 |
September 24, 2012 |
|
- Duluth Clinic
Duluth, Minnesota, United States - Memorial Sloan-Kettering Cancer Center
New York, New York, United States - Cross Cancer Institute
Edmonton, Alberta, Canada - (and 63 more...)
|
|
| 93 |
NCT02354586 |
Active, not recruiting |
A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens |
|
|
Interventional
|
Phase 2 |
- Tesaro, Inc.
- Facing Our Risk of Cancer Empowered
- Myriad Genetics, Inc.
|
Industry / Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Evaluate antitumor activity of niraparib
- Evaluate durability of anti-cancer activity (i.e. time from first response, CR or PR until disease progression).
- Evaluate antitumor activity of niraparib in HRD+ and gBRCAmut
- (and 4 more...)
|
500 |
Female |
18 Years and older (Adult, Older Adult) |
NCT02354586 |
PR-30-5020-C |
QUADRA |
March 2015 |
October 2017 |
December 2019 |
February 3, 2015 |
October 22, 2018 |
|
- Chandler, Arizona, United States
- Phoenix, Arizona, United States
- Tucson, Arizona, United States
- (and 46 more...)
|
|
| 94 |
NCT00662233 |
Completed |
Combination Chemotherapy in Treating Patients With Sarcoma |
|
- Drug: cyclophosphamide
- Drug: doxorubicin hydrochloride
- Drug: etoposide
- (and 8 more...)
|
Interventional
|
Early Phase 1 |
- Mayo Clinic
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Primary Purpose: Treatment
|
- Efficacy in terms of long-term disease-free survival
- Clinical response of the tumors
- Pathologic response of the tumors
- Long term disease-free survival
|
28 |
All |
up to 21 Years (Child, Adult) |
NCT00662233 |
CDR0000582271
P30CA015083
919110
542-91
0791 |
|
October 1991 |
October 21, 2013 |
October 21, 2013 |
April 21, 2008 |
October 8, 2018 |
|
- Mayo Clinic
Rochester, Minnesota, United States
|
|
| 95 |
NCT01493505 |
Terminated |
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer |
- Fallopian Tube Cancer
- Ovarian Cancer
- Peritoneal Cancer
|
- Drug: AMG 386
- Drug: Paclitaxel
- Drug: AMG 386 Placebo
- Drug: Carboplatin
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Progression free survival
- Overall survival (OS)
- Incidence of adverse events and significant laboratory abnormalities
- (and 6 more...)
|
1015 |
Female |
18 Years and older (Adult, Older Adult) |
NCT01493505 |
20101129
TRINOVA-3 20101129/ENGOT-ov2 |
|
January 2012 |
March 2016 |
December 2016 |
December 16, 2011 |
February 23, 2017 |
|
- Research Site
Birmingham, Alabama, United States - Research Site
Mobile, Alabama, United States - Research Site
Anchorage, Alaska, United States - (and 307 more...)
|
|
| 96 |
NCT03323398 |
Recruiting |
Dose Escalation and Efficacy Study of mRNA 2416 for Intratumoral Injection to Patients With Advanced Malignancies |
- Relapsed/Refractory Solid Tumor Malignancies or Lymphoma
|
|
Interventional
|
Phase 1
Phase 2 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of subjects with dose limiting toxicities (DLTs)
- Percentage of subjects with adverse events (AEs)
- ORR in patients with ovarian cancer based on RECIST v1.1
- (and 8 more...)
|
78 |
All |
18 Years and older (Adult, Older Adult) |
NCT03323398 |
mRNA-2416-P101 |
|
August 9, 2017 |
June 2020 |
October 2020 |
October 27, 2017 |
February 6, 2019 |
|
- University of Colorado Hospital
Aurora, Colorado, United States - Massachusetts General Hospital
Boston, Massachusetts, United States - Henry Ford Hospital
Detroit, Michigan, United States - (and 3 more...)
|
|
| 97 |
NCT02315430 |
Active, not recruiting |
Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
- Fallopian Tube Clear Cell Adenocarcinoma
- Ovarian Clear Cell Adenocarcinoma
- Recurrent Fallopian Tube Carcinoma
- (and 2 more...)
|
- Drug: Cabozantinib S-malate
- Other: Laboratory Biomarker Analysis
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free survival
- Complete or partial objective tumor response, evaluated using the RECIST v1.1
- Incidence of toxicity as assessed by CTCAE v4
- Overall survival
|
34 |
Female |
18 Years and older (Adult, Older Adult) |
NCT02315430 |
NCI-2014-02411
NRG-GY001
U10CA180868 |
|
April 1, 2015 |
April 30, 2019 |
|
December 11, 2014 |
February 6, 2019 |
|
- Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - Alaska Oncology and Hematology LLC
Anchorage, Alaska, United States - (and 407 more...)
|
|
| 98 |
NCT00849667 |
Completed |
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse |
|
- Drug: MORAb-003 (farletuzumab)
- Drug: 0.9% Saline
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Progression-free survival using by RECIST
- Overall Survival, CA-125 PFS, GCIG PFS, Length of first versus second remission, Tumor Response,Serologic Response (CA-125), Quality of Life, Resource utilization and PK DDI substudy.
|
1100 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00849667 |
MORAb003-004 |
|
April 2009 |
December 2012 |
April 2013 |
February 24, 2009 |
July 20, 2015 |
|
- University Of Alabama At Birmingham
Birmingham, Alabama, United States - Oncology Specialties, PC
Huntsville, Alabama, United States - Arizona Hematology & Oncology Associates
Phoenix, Arizona, United States - (and 372 more...)
|
|
| 99 |
NCT03180307 |
Recruiting |
OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer |
|
- Drug: OTL38
- Device: near infrared imaging
|
Interventional
|
Phase 3 |
- On Target Laboratories, LLC
- SynteractHCR
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Other
|
- Efficacy patient level
- Patient false positive rate
|
147 |
Female |
18 Years to 85 Years (Adult, Older Adult) |
NCT03180307 |
OTL-2016-OTL38-006 |
|
January 26, 2018 |
August 2019 |
November 2019 |
June 8, 2017 |
January 9, 2019 |
|
- University of Arizona
Tucson, Arizona, United States - City of Hope Medical Center
Duarte, California, United States - University of CA at Irvine Chao Cancer Center
Orange, California, United States - (and 7 more...)
|
|
| 100 |
NCT02289950 |
Active, not recruiting |
A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Subjects With Low CA125 Platinum-Sensitive Ovarian Cancer |
- Platinum-Sensitive Ovarian Cancer in First Relapse
|
- Drug: Farletuzumab
- Drug: Placebo
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Progression Free Survival (PFS) based on the investigators' radiographic assessments utilizing RECIST 1.1 criteria
- Overall Survival Rate
- Length of First vs Second Platinum-Free Interval
- (and 3 more...)
|
215 |
Female |
18 Years and older (Adult, Older Adult) |
NCT02289950 |
MORAb-003-011 |
|
March 19, 2015 |
May 31, 2019 |
May 31, 2019 |
November 13, 2014 |
January 23, 2019 |
|
- Phoenix, Arizona, United States
- Los Angeles, California, United States
- Orange, California, United States
- (and 65 more...)
|
|
Create an RSS feed from your search for:
Download the search results for: